175 related articles for article (PubMed ID: 11587482)
1. Sinusoidal efflux of taurocholate is enhanced in Mrp2-deficient rat liver.
Akita H; Suzuki H; Sugiyama Y
Pharm Res; 2001 Aug; 18(8):1119-25. PubMed ID: 11587482
[TBL] [Abstract][Full Text] [Related]
2. Sinusoidal efflux of taurocholate correlates with the hepatic expression level of Mrp3.
Akita H; Suzuki H; Sugiyama Y
Biochem Biophys Res Commun; 2002 Dec; 299(5):681-7. PubMed ID: 12470631
[TBL] [Abstract][Full Text] [Related]
3. Increased hepatic and renal expressions of multidrug resistance-associated protein 3 in Eisai hyperbilirubinuria rats.
Kuroda M; Kobayashi Y; Tanaka Y; Itani T; Mifuji R; Araki J; Kaito M; Adachi Y
J Gastroenterol Hepatol; 2004 Feb; 19(2):146-53. PubMed ID: 14731123
[TBL] [Abstract][Full Text] [Related]
4. Determination of phase I metabolic enzyme activities in liver microsomes of Mrp2 deficient TR- and EHBR rats.
Newton DJ; Wang RW; Evans DC
Life Sci; 2005 Jul; 77(10):1106-15. PubMed ID: 15913659
[TBL] [Abstract][Full Text] [Related]
5. Hepatobiliary disposition of the metabolically stable opioid peptide [D-Pen2, D-Pen5]-enkephalin (DPDPE): pharmacokinetic consequences of the interplay between multiple transport systems.
Hoffmaster KA; Zamek-Gliszczynski MJ; Pollack GM; Brouwer KL
J Pharmacol Exp Ther; 2004 Dec; 311(3):1203-10. PubMed ID: 15302892
[TBL] [Abstract][Full Text] [Related]
6. Characterization of bile acid transport mediated by multidrug resistance associated protein 2 and bile salt export pump.
Akita H; Suzuki H; Ito K; Kinoshita S; Sato N; Takikawa H; Sugiyama Y
Biochim Biophys Acta; 2001 Mar; 1511(1):7-16. PubMed ID: 11248200
[TBL] [Abstract][Full Text] [Related]
7. Kinetic analysis of hepatobiliary transport for conjugated metabolites in the perfused liver of mutant rats (EHBR) with hereditary conjugated hyperbilirubinemia.
Takenaka O; Horie T; Kobayashi K; Suzuki H; Sugiyama Y
Pharm Res; 1995 Nov; 12(11):1746-55. PubMed ID: 8592681
[TBL] [Abstract][Full Text] [Related]
8. Increase in bile flow and biliary excretion of glutathione-derived sulfhydryls in rats by drug-metabolizing enzyme inducers is mediated by multidrug resistance protein 2.
Johnson DR; Habeebu SS; Klaassen CD
Toxicol Sci; 2002 Mar; 66(1):16-26. PubMed ID: 11861969
[TBL] [Abstract][Full Text] [Related]
9. OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker.
Nakagomi-Hagihara R; Nakai D; Kawai K; Yoshigae Y; Tokui T; Abe T; Ikeda T
Drug Metab Dispos; 2006 May; 34(5):862-9. PubMed ID: 16501004
[TBL] [Abstract][Full Text] [Related]
10. Different biliary excretion systems for glucuronide and sulfate of a model compound; study using Eisai hyperbilirubinemic rats.
Takenaka O; Horie T; Suzuki H; Sugiyama Y
J Pharmacol Exp Ther; 1995 Sep; 274(3):1362-9. PubMed ID: 7562509
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of xenobiotic detoxification system mediated by efflux transporters].
Suzuki H
Yakugaku Zasshi; 1999 Nov; 119(11):822-34. PubMed ID: 10590710
[TBL] [Abstract][Full Text] [Related]
12. The influence of glucagon on the hepatic transport of taurocholate in isolated perfused rat liver: kinetic analysis by the multiple indicator dilution technique.
Miyauchi S; Sawada Y; Iga T; Hanano M; Sugiyama Y
Biol Pharm Bull; 1993 Aug; 16(8):791-5. PubMed ID: 8220327
[TBL] [Abstract][Full Text] [Related]
13. Biliary excretion of 17beta-estradiol 17beta-D-glucuronide is predominantly mediated by cMOAT/MRP2.
Morikawa A; Goto Y; Suzuki H; Hirohashi T; Sugiyama Y
Pharm Res; 2000 May; 17(5):546-52. PubMed ID: 10888306
[TBL] [Abstract][Full Text] [Related]
14. Mrp2 is involved in benzylpenicillin-induced choleresis.
Ito K; Koresawa T; Nakano K; Horie T
Am J Physiol Gastrointest Liver Physiol; 2004 Jul; 287(1):G42-9. PubMed ID: 15194559
[TBL] [Abstract][Full Text] [Related]
15. Stereoselective hepatic disposition of a diastereomeric pair of alphavbeta3 antagonists in rat.
Prueksaritanont T; Xu X; Deluna P; Yamazaki M; Lin JH
Xenobiotica; 2003 Nov; 33(11):1125-37. PubMed ID: 14660176
[TBL] [Abstract][Full Text] [Related]
16. The mutant Eisai hyperbilirubinemic rat is resistant to bile acid-induced cholestasis and cytotoxicity.
Hoshino M; Hayakawa T; Hirano A; Kamiya Y; Ohiwa T; Tanaka A; Kumai T; Inagaki T; Miyaji M; Takeuchi T
Hepatology; 1994 Oct; 20(4 Pt 1):932-9. PubMed ID: 7927235
[TBL] [Abstract][Full Text] [Related]
17. Impact of Mrp2 on the biliary excretion and intestinal absorption of furosemide, probenecid, and methotrexate using Eisai hyperbilirubinemic rats.
Chen C; Scott D; Hanson E; Franco J; Berryman E; Volberg M; Liu X
Pharm Res; 2003 Jan; 20(1):31-7. PubMed ID: 12608533
[TBL] [Abstract][Full Text] [Related]
18. Both cMOAT/MRP2 and another unknown transporter(s) are responsible for the biliary excretion of glucuronide conjugate of the nonpeptide angiotensin II antagonist, telmisaltan.
Nishino A; Kato Y; Igarashi T; Sugiyama Y
Drug Metab Dispos; 2000 Oct; 28(10):1146-8. PubMed ID: 10997931
[TBL] [Abstract][Full Text] [Related]
19. Ticlopidine, a cholestatic liver injury-inducible drug, causes dysfunction of bile formation via diminished biliary secretion of phospholipids: involvement of biliary-excreted glutathione-conjugated ticlopidine metabolites.
Yoshikado T; Takada T; Yamamoto H; Tan JK; Ito K; Santa T; Suzuki H
Mol Pharmacol; 2013 Feb; 83(2):552-62. PubMed ID: 23220748
[TBL] [Abstract][Full Text] [Related]
20. Hepatic expression of multidrug resistance-associated protein-like proteins maintained in eisai hyperbilirubinemic rats.
Hirohashi T; Suzuki H; Ito K; Ogawa K; Kume K; Shimizu T; Sugiyama Y
Mol Pharmacol; 1998 Jun; 53(6):1068-75. PubMed ID: 9614210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
